Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Related Content
Researchers find significant increase in childhood astigmatism post-COVID
March 23rd 2025

Researchers find significant increase in childhood astigmatism post-COVID

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients
March 3rd 2025

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder
February 22nd 2025

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder

© 2025 MJH Life Sciences

All rights reserved.